5-Aminosalicylic acid ameliorates dextran sulfate sodium-induced colitis in mice by modulating gut microbiota and bile acid metabolism
- 1 August 2022
- journal article
- research article
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 79 (8) , 1-18
Abstract
Colitis develops via the convergence of environmental, microbial, immunological, and genetic factors. The medicine 5-aminosalicylic acid (5-ASA) is widely used in clinical practice for colitis (especially ulcerative colitis) treatment. However, the significance of gut microbiota in the protective effect of 5-ASA on colitis has not been explored. Using a dextran sulfate sodium (DSS)-induced colitis mouse model, we found that 5-ASA ameliorated colitis symptoms in DSS-treated mice, accompanied by increased body weight gain and colon length, and a decrease in disease activity index (DAI) score and spleen index. Also, 5-ASA alleviated DSS-induced damage to colonic tissues, as indicated by suppressed inflammation and decreased tight junction, mucin, and water–sodium transport protein levels. Moreover, the 16S rDNA gene sequencing results illustrated that 5-ASA reshaped the disordered gut microbiota community structure in DSS-treated mice by promoting the abundance of Bifidobacterium, Lachnoclostridium, and Anaerotruncus, and reducing the content of Alloprevotella and Desulfovibrio. Furthermore, 5-ASA improved the abnormal metabolism of bile acids (BAs) by regulating the Farnesoid X receptor (FXR) and Takeda G-protein-coupled receptor 5 (TGR5) signaling pathways in DSS-treated mice. In contrast, 5-ASA did not prevent the occurrence of colitis in mice with gut microbiota depletion, confirming the essential role of gut microbiota in colitis treatment by 5-ASA. In conclusion, 5-ASA can ameliorate DSS-induced colitis in mice by modulating gut microbiota and bile acid metabolism. These findings documented the new therapeutic mechanisms of 5-ASA in clinical colitis treatment.Keywords
Funding Information
- Department of Science and Technology of Hubei Province (2020CFB526)
- Department of Science and Technology of Hubei Province (2021CFA014)
- Hubei Province Health Committee (ZY2021Z005, ZY2021M015, ZY2021Q034)
- National Natural Science Foundation of China (81873098)
- Project of Hubei Hospital of Traditional Chinese Medicine (2021YJKT-16)
This publication has 63 references indexed in Scilit:
- Knockdown of aquaporin 3 is involved in intestinal barrier integrity impairmentFEBS Letters, 2011
- In PSC with Colitis Treated with UDCA, Most Colonic Carcinomas Develop in the First Years After the Start of TreatmentDigestive Diseases and Sciences, 2011
- Comparison of Prostaglandin E2 Receptor Subtype 4 Agonist and Sulfasalazine in Mouse Colitis Prevention and TreatmentThe Journal of Pharmacology and Experimental Therapeutics, 2010
- Desulfovibrio Bacterial Species Are Increased in Ulcerative ColitisDiseases of the Colon & Rectum, 2010
- Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasomeGut, 2010
- Reaction of 5-Aminosalicylic Acid with Peroxyl Radicals: Protection and Recovery by Ascorbic Acid and Amino AcidsPharmaceutical Research, 2005
- Aquaporin expression is downregulated in a murine model of colitis and in patients with ulcerative colitis, Crohn’s disease and infectious colitisCell and tissue research, 2004
- Inflammatory Bowel DiseaseNew England Journal of Medicine, 2002
- Chemoprevention of N-Methylnitrosourea-induced Colon Carcinogenesis by Ursodeoxycholic Acid-5-aminosalicylic Acid Conjugate in F344 RatsJapanese Journal of Cancer Research, 2002
- Colon tumor promotion: is it a selection process? Effects of cholate, phytate, and food restriction in rats on proliferation and apoptosis in normal and aberrant cryptsCancer Letters, 1997